Close Menu

NEW YORK (GenomeWeb) – Loxo Oncology announced today that it has formed a collaboration with Roche subsidiary Ventana Medical Systems to develop and commercialize a test to identify patients likely to respond to the cancer drug larotrectinib.

Loxo's larotrectinib — also known as LOXO-101 — is an oral inhibitor of tropomyosin receptor kinases (TRK), a family of proteins associated with cellular signaling and tumor growth. The drug is currently under phase I and II testing as a treatment for tumors with TRK fusions.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.